BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
SCD411: trial readouts and FDA decisions
0 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 1 FDA event(s) in the last 12 months. Sponsors: Sam Chun Dang Pharm. Co. Ltd., SamChunDang Pharm. Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| No trials in this window. | ||||||
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-08-18 | Complete response letter | complete response | SamChunDang Pharm. Co., Ltd. | SCD411 | CRL 2026-08-18: SamChunDang Pharm. Co., Ltd. BLA 761494 (SCD411) |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-05-27 | P2 | Sam Chun Dang Pharm. Co. Ltd. | NCT07501052 Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic | Neovascular (Wet) Age-Related Macular Degeneration; Retinal Vein Occlusion; Diabetic Macular Edema; | completed | 33 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.